News
HBIO
6.66
-0.22%
-0.02
Harvard Bioscience Price Target Raised to $7.50/Share From $6.00 by Benchmark
Dow Jones · 4d ago
Harvard Bioscience Is Maintained at Speculative Buy by Benchmark
Dow Jones · 4d ago
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5
Benzinga · 4d ago
Harvard Bioscience's Q2 Revenue Rises 11%; Raises FY26 Growth Outlook
NASDAQ · 5d ago
Harvard Bioscience Advances Transformation with Project Viking Launch
TipRanks · 5d ago
Harvard Bioscience beats top-line and bottom-line estimates; gives Q3 and raises FY2026 outlook
Seeking Alpha · 5d ago
*Harvard Bioscience Sees 3Q Rev $21M-$22.6M >HBIO
Dow Jones · 5d ago
*Harvard Bioscience Sees 2026 Revenue Growth of 3% to 5% >HBIO
Dow Jones · 5d ago
Harvard Bioscience Sees FY2026 Sales $89.147M-$90.877M vs $88.600M Est.
Benzinga · 5d ago
Harvard Bioscience Sees Q3 Sales $21.000M-$22.600M vs $21.850M Est
Benzinga · 5d ago
Press Release: Harvard Bioscience Announces -3-
Dow Jones · 5d ago
Press Release: Harvard Bioscience Announces -2-
Dow Jones · 5d ago
*Harvard Bioscience 2Q Rev $22.7M >HBIO
Dow Jones · 5d ago
Press Release: Harvard Bioscience Announces Second Quarter 2026 Financial Results
Dow Jones · 5d ago
*Harvard Bioscience 2Q Loss $2.91M >HBIO
Dow Jones · 5d ago
*Harvard Bioscience 2Q Adj Loss/Shr 14c >HBIO
Dow Jones · 5d ago
Harvard Bioscience: Q2 Earnings Snapshot
Barchart · 5d ago
Weekly Report: what happened at HBIO last week (0803-0807)?
Weekly Report · 6d ago
Weekly Report: what happened at HBIO last week (0727-0731)?
Weekly Report · 08/03 10:09
Weekly Report: what happened at HBIO last week (0720-0724)?
Weekly Report · 07/27 10:13
More
Webull provides a variety of real-time HBIO stock news. You can receive the latest news about Harvard Biosci through multiple platforms. This information may help you make smarter investment decisions.
About HBIO
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.